Axol Bioscience: Valuation, Funding & Investors
Axol Bioscience develops and supplies high-quality induced pluripotent stem cell (iPSC)-derived cells, reagents, and specialist services to pharmaceutical, biotechnology, contract research organizations, and academic institutions worldwide. The company focuses on providing physiologically relevant iPSC-derived disease models and scalable cell manufacturing to support drug discovery and disease research across neuroscience, ophthalmology, and cardiovascular domains.
Leadership & Board
- Current Number of Employees
- 60
- Current LinkedIn Followers
- 13,442
Latest Estimated Valuation
- Total Amount Raised
- $3M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $3M
- Latest Funding Round
- Investment
Company Momentum Positive
Axol Bioscience LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Axol Bioscience had 60 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Axol Bioscience had 13,442 followers as of October 26, 2026. The number of followers increased by 38 (0.28%) week-over-week.
Main Enterprise Clients
A snapshot of major enterprise customers that use this private company’s products or services, highlighting its commercial reach and market adoption.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 13, 2026 | Investment | $2.80M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| BroadOak Capital Partners | Investment |
| Roslin Foundation | Investment |
Similar Companies
A snapshot of private companies similar to Axol Bioscience, helping you discover and navigate related company profiles.
Related News and Analysis
